Antiseizure medication discovery: Recent and future paradigm shifts.
disrupting innovation
drug discovery
epilepsy
innovation
low-affinity ligand
multi-target
multi-target drugs
network pharmacology
partial agonist
radical innovation
systems pharmacology
Journal
Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
21
01
2022
received:
24
05
2021
accepted:
21
01
2022
pubmed:
29
1
2022
medline:
3
8
2022
entrez:
28
1
2022
Statut:
ppublish
Résumé
Despite the ever-increasing number of available options for the treatment of epilepsies and the remarkable advances on the understanding of their pathophysiology, the proportion of refractory patients has remained approximately unmodified during the last 100 years. How efficient are we translating positive outcomes from basic research to clinical trials and/or the clinical scenario? It is possible that fresh thinking and exploration of new paradigms are required to arrive at truly novel therapeutic solutions, as seemingly proven by recently approved first-in-class antiseizure medications and drug candidates undergoing late clinical trials. Here, the author discusses some approximations in line with the network pharmacology philosophy, which may result in highly innovative (and, hopefully, safer and/or more efficacious) medications for the control of seizures, as embodied with some recent examples in the field, namely tailored multi-target agents and low-affinity ligands.
Identifiants
pubmed: 35090197
doi: 10.1002/epi4.12581
pmc: PMC9340309
doi:
Substances chimiques
Anticonvulsants
0
Ligands
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S133-S141Informations de copyright
© 2022 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Pharmaceuticals (Basel). 2014 Jan 23;7(2):113-35
pubmed: 24463342
Epilepsia. 2020 Nov;61(11):2340-2364
pubmed: 33190243
Epilepsy Res. 2017 Jan;129:8-16
pubmed: 27875747
Front Behav Neurosci. 2020 Dec 15;14:611278
pubmed: 33384591
Epilepsy Curr. 2009 Mar-Apr;9(2):47-52
pubmed: 19421380
Epilepsia. 2016 Apr;57(4):538-48
pubmed: 26920914
Neuropharmacology. 2015 Feb;89:122-35
pubmed: 25242737
Cochrane Database Syst Rev. 2012 Sep 12;(9):CD001901
pubmed: 22972056
Front Cell Neurosci. 2019 Apr 30;13:172
pubmed: 31114484
Expert Opin Drug Discov. 2016;11(2):121-5
pubmed: 26593688
Nat Rev Neurol. 2020 Nov;16(11):595-596
pubmed: 33024326
Drug Des Devel Ther. 2017 Oct 04;11:2921-2930
pubmed: 29042752
Seizure. 2011 Jun;20(5):359-68
pubmed: 21292505
Curr Pharm Des. 2016;22(21):3164-70
pubmed: 26951108
Ther Clin Risk Manag. 2019 Jul 26;15:951-955
pubmed: 31440057
CNS Drugs. 2014 Jan;28(1):29-43
pubmed: 24357084
Epileptic Disord. 2020 Jan 1;22(S1):10-15
pubmed: 32053110
Biosystems. 2016 Mar;141:1-9
pubmed: 26723231
Neurosci Lett. 2001 Jun 22;306(1-2):5-8
pubmed: 11403944
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1310-1321
pubmed: 32529860
Br J Pharmacol. 2011 Jun;163(4):713-21
pubmed: 21615387
Expert Opin Drug Discov. 2016 Oct;11(10):1001-16
pubmed: 27454246
Mol Pharmacol. 2012 Aug;82(2):199-208
pubmed: 22554805
Med Hypotheses. 2009 Mar;72(3):297-305
pubmed: 19046822
Epilepsia Open. 2022 Aug;7 Suppl 1:S133-S141
pubmed: 35090197
Nat Chem Biol. 2008 Nov;4(11):682-90
pubmed: 18936753
Brief Bioinform. 2017 Mar 1;18(2):321-332
pubmed: 26962012
Neurobiol Dis. 2020 Feb;134:104664
pubmed: 31678583
PLoS One. 2011;6(6):e20763
pubmed: 21695113
Phys Rev E Stat Nonlin Soft Matter Phys. 2005 May;71(5 Pt 1):051909
pubmed: 16089573
Epilepsy Behav. 2020 Apr;105:106989
pubmed: 32169824
Expert Rev Neurother. 2019 Oct;19(10):913-925
pubmed: 31335226
Br J Pharmacol. 2011 Mar;162(6):1239-49
pubmed: 21091654
Pharmacol Ther. 2013 Jun;138(3):333-408
pubmed: 23384594
Nat Rev Drug Discov. 2006 Aug;5(8):689-702
pubmed: 16883306
Drug Discov Today. 2013 Nov;18(21-22):1067-73
pubmed: 23850704
Epilepsy Res. 2013 Mar;104(1-2):26-34
pubmed: 23158096
Epilepsy Behav. 2021 Aug;121(Pt B):106451
pubmed: 31420290
Pharmacol Res. 2013 Nov;77:39-46
pubmed: 24056205
Drugs R D. 2017 Sep;17(3):329-339
pubmed: 28741150
Pharmacol Rev. 2020 Jul;72(3):606-638
pubmed: 32540959
Epilepsia. 2010 Jun;51(6):1069-77
pubmed: 19889013
Seizure. 2018 Oct;61:98-103
pubmed: 30118932
Epilepsia. 2002 Jan;43(1):9-18
pubmed: 11879381
Epilepsy Res. 2012 Feb;98(2-3):104-15
pubmed: 22055355
Epilepsia. 2013 Jul;54(7):1186-94
pubmed: 23750799
Brain. 2019 Jun 1;142(6):1616-1630
pubmed: 30932156
Continuum (Minneap Minn). 2019 Apr;25(2):508-536
pubmed: 30921021
Epilepsy Behav. 2015 Nov;52(Pt A):165-8
pubmed: 26432008
Seizure. 2017 Oct;51:121-132
pubmed: 28854405
Nat Rev Drug Discov. 2007 Mar;6(3):202-10
pubmed: 17318209
Epilepsia. 2018 Oct;59(10):1842-1866
pubmed: 30368788
Epilepsia. 2020 Nov;61(11):2365-2385
pubmed: 33165915
Seizure. 2016 Jul;39:28-33
pubmed: 27236448
Eur Urol. 2004 Jul;46(1):9-14
pubmed: 15183543
Nat Rev Drug Discov. 2006 Feb;5(2):160-70
pubmed: 16424917
Neuropharmacology. 2020 Apr;166:107811
pubmed: 31790717